Cyclacel Pharmaceuticals (CYCC) Competitors $8.89 -0.01 (-0.11%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$9.32 +0.43 (+4.88%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC vs. CGTX, BRNS, LTRN, IFRX, HOWL, UNCY, DTIL, PDSB, ELYM, and KLRSShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Cognition Therapeutics (CGTX), Barinthus Biotherapeutics (BRNS), Lantern Pharma (LTRN), InflaRx (IFRX), Werewolf Therapeutics (HOWL), Unicycive Therapeutics (UNCY), Precision BioSciences (DTIL), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), and Kalaris Therapeutics (KLRS). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Its Competitors Cognition Therapeutics Barinthus Biotherapeutics Lantern Pharma InflaRx Werewolf Therapeutics Unicycive Therapeutics Precision BioSciences PDS Biotechnology Eliem Therapeutics Kalaris Therapeutics Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations. Is CYCC or CGTX more profitable? Cognition Therapeutics' return on equity of -251.23% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cyclacel PharmaceuticalsN/A -3,648.09% -145.49% Cognition Therapeutics N/A -251.23%-130.75% Do insiders & institutionals have more ownership in CYCC or CGTX? 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 14.4% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has stronger earnings & valuation, CYCC or CGTX? Cyclacel Pharmaceuticals has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclacel Pharmaceuticals$40K351.16-$11.21M-$839.58-0.01Cognition TherapeuticsN/AN/A-$33.97M-$0.67-2.48 Do analysts prefer CYCC or CGTX? Cognition Therapeutics has a consensus price target of $2.83, indicating a potential upside of 70.68%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Cyclacel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Cognition Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer CYCC or CGTX? In the previous week, Cognition Therapeutics had 7 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 11 mentions for Cognition Therapeutics and 4 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 1.22 beat Cognition Therapeutics' score of 0.75 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CYCC or CGTX? Cyclacel Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500. SummaryCognition Therapeutics beats Cyclacel Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.10M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.0120.4930.2925.74Price / Sales351.16356.37463.41115.79Price / CashN/A43.0338.2159.48Price / Book-0.158.608.826.15Net Income-$11.21M-$54.65M$3.25B$265.06M7 Day Performance1.25%5.86%3.70%2.60%1 Month Performance-27.90%8.86%5.84%2.83%1 Year Performance-97.19%13.33%29.92%25.58% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals1.6676 of 5 stars$8.89-0.1%N/A-97.4%$14.10M$40K-0.0114News CoveragePositive NewsEarnings ReportGap DownCGTXCognition Therapeutics3.4595 of 5 stars$0.86+13.8%$2.83+230.0%+169.6%$55.44MN/A-1.2820Short Interest ↓Analyst RevisionBRNSBarinthus Biotherapeutics2.4284 of 5 stars$1.14-14.9%$6.25+448.2%-4.1%$54.06M$14.97M-0.66107Short Interest ↑LTRNLantern Pharma2.7084 of 5 stars$4.33-13.2%$25.00+477.4%+16.0%$53.82MN/A-2.3520Earnings ReportIFRXInflaRx3.2331 of 5 stars$0.82+2.8%$6.60+701.9%-38.7%$53.72M$180K-1.0360Gap DownHOWLWerewolf Therapeutics3.7225 of 5 stars$1.18+0.9%$8.33+606.2%-33.7%$52.50M$1.88M-0.7140News CoverageUNCYUnicycive Therapeutics2.6507 of 5 stars$4.01-2.0%$60.00+1,396.3%+46.4%$51.70M$680K-0.799News CoverageEarnings ReportGap DownDTILPrecision BioSciences4.0629 of 5 stars$4.35-0.7%$47.00+980.5%-46.8%$51.63M$68.70M-0.49200Analyst RevisionPDSBPDS Biotechnology2.0651 of 5 stars$1.08-2.7%$9.00+733.3%-60.3%$50.74MN/A-1.1520News CoverageEarnings ReportELYMEliem TherapeuticsN/A$1.70+1.2%N/A-72.9%$50.58MN/A-3.219Gap UpKLRSKalaris Therapeutics2.1446 of 5 stars$2.66-0.4%$3.00+12.8%N/A$49.94MN/A0.00110Earnings Report Related Companies and Tools Related Companies Cognition Therapeutics Competitors Barinthus Biotherapeutics Competitors Lantern Pharma Competitors InflaRx Competitors Werewolf Therapeutics Competitors Unicycive Therapeutics Competitors Precision BioSciences Competitors PDS Biotechnology Competitors Eliem Therapeutics Competitors Kalaris Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCC) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access